Engaging Newly Diagnosed Men About Cancer Treatment Options

This research is being done to better understand how a new lab test called the Oncotype DX
Prostate Cancer Assay may impact what treatment men decide to get and how they feel and think
about their choice of treatment. The study will compare men who receive this new lab test
with men who receive the usual counseling given to men after they get a new diagnosis of
prostate cancer. Prostate cancer is sometimes slow-growing and sometimes fast-growing.
Healthcare providers are searching for better ways to predict how each tumor will behave so
that each man can make a better decision about when to receive treatment. The Oncotype DX lab
test uses leftover prostate biopsy tissue to generate a Genomic Prostate Score (GPS). The GPS
is related to the risk of a fast-growing cancer being discovered if surgery is performed to
remove a man's prostate. The goal of this study is to find out if this test helps men when
they are deciding how their prostate cancer will be treated. Treatment options include
surgery to remove the prostate, radiation therapy, or an approach called "active
surveillance" in which there is no immediate therapy and the tumor is watched using prostate
specific antigen (PSA) tests and repeat biopsies.